Buy viagra

Online DrugStore

Erectile Dysfunction Treatment

Home | Premature ejaculation 1 | Premature ejaculation 2 | Symptoms of prostatitis | Innovation E.D. treatment | Facts impotence | E.D. treatment | BUY VIAGRA ONLINE

Now consider these methods in more detail.

Psychotherapy

Professionals often turn to this method for the treatment of erectile dysfunction with psychological factors, using methods that eradicate anxiety associated with intercourse. In this case, the partner of the patient can help with methods, which imply a gradual increase in the excitation in an intimate setting. Such techniques also can help relieve anxiety during treatment with physical causes of erectile dysfunction.

Drug therapy

A variety of drugs for the treatment of erectile dysfunction affects. They can be used orally, injected directly into the penis, or even inserted into the urethra at the tip of the penis. As mentioned in previous posts, and March 1998, the Ministry of health approved medication for the treatment of erectile dysfunction “Viagra“. A year later, was approved vardenafil hydrochloride Levitra and tadalafil is Cialis. These drugs are the first pill to treat erectile dysfunction. All of these drugs are Viagra, Levitra, and Cialis belong to the group of phosphodiesterase inhibitors. Taken 30-45 minutes before sexual intercourse, these drugs relax the smooth muscles of the penis during sexual stimulation, allowing you to increase the blood flow.




Erectile dysfunction treatment new results

 New results for the treatment of erectile dysfunction

Palatin Technologies Inc. (Palatin Technologies, Inc. NYSE Amex: PTN) announced positive results from the first phase of application subcutaneous administration of bremelanotide (bremelanotide), an agonist of the melanocortin (melanocortin) as a drug for the treatment of erectile dysfunction in men and sexual dysfunction in women. Clinical studies have shown that subcutaneous administration of the drug at therapeutic levels causes changes in the blood plasma, thereby causing a rise in blood pressure, it has a beneficial effect on erection.

The analysis of the impact of bremelanotide on blood pressure, the company raised an independent group of experts in the field of cardiovascular disease for a comprehensive study of the safety and relevance of research conducted using bremelanotide. Based on the recommendations of experts, Palatin technologies is going to attract the attention of the Federation of nutrition and health, to address the future of bremelanotide as a drug for the treatment of erectile dysfunction (ED).

Meeting Palatin Technologies, Inc. and the FDA (Food and Drug Administration) is planned for late 2010. The core of the meeting will be the question of the beginning of the second phase of research Bremelanotide (Bremelanotide), as monotherapy, or in combination with inhibitors fosfodiesterazy the fifth type, such as Viagra, Cialis or Levitra. Basically, it will have an effect on those patients who are not sensitive or low sensitivity to PDE-5 inhibitor therapy.

The aim of the second phase is the study and evaluation of the blood pressure levels as a consequence of subcutaneous injection of bremelanotide healthy men aged 45-65 years, under controlled conditions, as well as the impact of bremelanotide in the blood plasma. In total, scientists have 49 direct and 19 indirect tasks tasks, questions which should give scientists in the research process of this substance, as surrogate, to create remedies for the treatment of erectile dysfunction and cardiovascular disease.

From the statement of the Executive Palatine, Charles Span: “the Commercial possibilities of bremelanotide as a means of treatment of erectile dysfunction – significant. 35 % of men with impotence for the treatment is not suitable for oral drugs. Moreover, here we deal with female sexual dysfunction, and it gives a huge market opportunity. To date, no FDA approved drug for the treatment of female sexual function.”